Alliancebernstein L.P. Anavex Life Sciences Corp. Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Alliancebernstein L.P. holds 107,840 shares of AVXL stock, worth $1.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

107,840

Previous 120,880 10.79%

Holding current value

$1.13 Million

Previous $510,000 20.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$4.11 - $7.04 $53,594 - $91,801	-13,040 Reduced 10.79%	107,840 $612,000
Q2 2024 Aug 14, 2024	BUY	$3.39 - $5.02 $137,227 - $203,209	40,480 Added 50.35%	120,880 $510,000
Q1 2024 May 14, 2024	SELL	$4.55 - $6.75 $34,762 - $51,570	-7,640 Reduced 8.68%	80,400 $409,000
Q4 2023 Feb 14, 2024	BUY	$5.04 - $9.95 $25,200 - $49,750	5,000 Added 6.02%	88,040 $819,000
Q3 2023 Nov 14, 2023	SELL	$6.55 - $9.37 $42,968 - $61,467	-6,560 Reduced 7.32%	83,040 $543,000
Q1 2022 May 13, 2022	BUY	$9.74 - $17.69 $1,948 - $3,538	200 Added 0.22%	89,600 $1.1 Million
Q2 2021 Jul 30, 2021	BUY	$10.16 - $28.86 $721,360 - $2.05 Million	71,000 Added 385.87%	89,400 $2.04 Million
Q1 2021 May 06, 2021	SELL	$5.17 - $16.13 $197,494 - $616,166	-38,200 Reduced 67.49%	18,400 $275,000
Q2 2020 Aug 13, 2020	BUY	$2.62 - $5.2 $72,574 - $144,040	27,700 Added 95.85%	56,600 $278,000
Q1 2020 May 14, 2020	BUY	$2.38 - $5.81 $68,782 - $167,909	28,900 New	28,900 $91,000
Q2 2018 Aug 13, 2018	SELL	$2.08 - $4.26 $61,776 - $126,522	-29,700 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$3.42 - $4.87 $101,574 - $144,639	29,700	29,700 $123,000

Others Institutions Holding AVXL

# of Institutions

161

Shares Held

27.4M

Call Options Held

515K

Put Options Held

838K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $818M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Anavex Life Sciences Corp. Transaction History